^
Association details:
| Biomarker: | EML4-ALK + ALK G1202R + LIPI-NTRK1 |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P84.18 - Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement
Published date:
01/12/2021
Excerpt:
A 43-year-old woman....stage IVa (T2bN2M1b) lung adenocarcinoma...Three different mutation type were detected, including the classical EML4-ALK fusion, the ALK G1202R acquired resistance mutation and a new fusion form of NTRK rearrangement (LIPI-NTRK1)...Ultimately, This patient had a progression-free survival of 7 months with crizotinib but of only one month with brigatinib treatment.
